Merck Reports Second-Quarter 2026 Sales of $16.6 Billion, Narrows Full-Year Outlook

Earnings
โดย Business Wire·Read original
Summary · why it matters

Merck & Co., Inc., Rahway, N.J., USA announced second-quarter 2026 worldwide sales of $16.6 billion, a 5% increase from the prior year, and narrowed its full-year 2026 sales outlook to between $66.3 billion and $67.3 billion. KEYTRUDA and KEYTRUDA QLEX sales reached $8.4 billion, including $463 million from the newly launched KEYTRUDA QLEX, while WINREVAIR sales grew 75% to $588 million and Animal Health sales rose 8% to $1.8 billion. The company reported a GAAP loss per share of $0.54 and a non-GAAP loss per share of $0.13, both reflecting a $2.31 per share charge for the acquisition of Terns Pharmaceuticals. Key regulatory milestones included U.S. FDA approval of LIPFENDRA, the first once-daily oral PCSK9 inhibitor, and positive Phase 3 results for the investigational sacituzumab tirumotecan in endometrial cancer and for a once-weekly oral HIV regimen of islatravir and lenacapavir in collaboration with Gilead. Merck now expects full-year non-GAAP EPS between $2.66 and $2.76, which includes charges of $2.43 per share related to the Terns acquisition.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 2 stocks
Merck & Company Inc
MRK
▲ PositiveCapitalrelevance

Q2 sales up 5%, narrowed full-year outlook, and regulatory/clinical progress

Gilead Sciences Inc
GILD
▲ PositiveTechnologyrelevance

Positive Phase 3 results for once-weekly oral HIV regimen in collaboration with Merck

Theme Impact 3

Off-coverage companies 1

Terns Pharmaceuticals, Inc.Private▼ Negative
Capitalrelevance

Acquisition by Merck results in $2.31 per share charge, impacting earnings

Related news

▲

Bristol Myers Sotyktu Shows Two-Year PsA Efficacy in POETYK Study

Bristol Myers Squibb announced positive two-year results from the late-stage POETYK PsA-2 study of Sotyktu, or deucravacitinib, including its open-label extension. Among patients entering the extension, clinical responses improved from week 16 through week 52 and were sustained through week 104, with robust results across ACR20/50/70 and Minimal Disease Activity in both continuous Sotyktu patients and those who switched from placebo at week 16. The safety profile remained consistent through week 104 with no new safety signals; adverse events occurred in 86.6% of 604 patients exposed to Sotyktu, while serious adverse events and discontinuations due to adverse events were reported in 12.6% and 7.6% of patients, respectively. Sotyktu, an oral selective tyrosine kinase 2 inhibitor approved in the United States and numerous other countries for moderate-to-severe plaque psoriasis and active psoriatic arthritis, generated $156 million in first-half 2026 revenues, up 24% year over year. Data from the POETYK SLE-1 and SLE-2 studies in systemic lupus erythematosus are expected later in 2026, while Amgen's Otezla and Takeda's investigational zasocitinib, whose new drug application the FDA recently accepted for plaque psoriasis, remain competitive threats.
BMY ▲
Biotech & Genomic Medicine ▲
Zacks Investment Research·19hRead more →
3

Novo's Denecimig Wins CHMP Backing for Hemophilia A in EU

Novo Nordisk said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of denecimig, also known as Mim8, for the treatment of hemophilia A, with or without inhibitors, in adults and children. Denecimig is a next-generation factor VIIIa mimetic bispecific antibody given subcutaneously as routine prophylaxis, with flexible dosing that includes once-monthly, every-two-week and weekly administration, and it is being developed as a prefilled pen. Novo expects to launch the drug in the first European countries in the fourth quarter of 2026 under the brand name Frehemgo, followed by a broader rollout across the European Union beginning in early 2027. The positive opinion is supported by data from the FRONTIER clinical program, which comprises five studies evaluating denecimig as a prophylactic treatment for hemophilia A across pediatric and adult populations, with or without inhibitors; in the FRONTIER 2 study denecimig significantly reduced annualized bleeding rates, results in children younger than 12 in FRONTIER 3 were consistent with those in adolescents and adults, and in FRONTIER 5 no new safety concerns were identified when participants switched directly from emicizumab to denecimig. The candidate is also under regulatory review in the United States for routine prophylaxis in adults and children with hemophilia A, with or without inhibitors, after Novo submitted a biologics license application to the FDA in September 2025. Novo already markets Alhemo for hemophilia A and B in patients with or without inhibitors.
ACIUALDXNOV.XETRAPGEN
Biotech & Genomic Medicine ▲
Zacks Investment Research·22hRead more →
▼impact 4

Trump to Announce Most Favored Nation Drug Pricing for Medicaid in All 50 States

President Trump will announce on Friday that Medicaid beneficiaries in all 50 states will receive Most Favored Nation pricing discounts on some prescription drugs. The White House Council of Economic Advisers projects the move will generate $27.6B in savings for state governments and $36.6B for the federal government over 10 years, according to Semafor, which broke the news. Trump is also scheduled to meet today with the governors of Arkansas, Mississippi, and South Dakota to discuss progress on lowering drug prices. Separately, an AARP Public Policy Institute report released in August found that applying MFN pricing to the top 10 drugs by Medicare Part D and Part B spending in 2025 would cut Medicare spending on those drugs from $273B to $76B between 2029 and 2033.
ABBVJNJLLYMRKNOV.XETRAPFE+1
Biotech & Genomic Medicine ▼
Seeking Alpha·23hRead more →
© 2026 MarketDXNews